Real-life experiences with omalizumab for the treatment of chronic urticaria.

@article{Sussman2014ReallifeEW,
  title={Real-life experiences with omalizumab for the treatment of chronic urticaria.},
  author={Gordon L. Sussman and Jacques Hebert and Carly S Barron and Jia Bian and Rose-Marie Caron-Guay and St{\'e}phanie Laflamme and Simon Stern},
  journal={Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology},
  year={2014},
  volume={112 2},
  pages={170-4}
}
BACKGROUND Evidence has shown that omalizumab, a subcutaneous anti-IgE monoclonal antibody, is highly effective for the treatment of chronic urticaria. OBJECTIVE To evaluate omalizumab 150 mg/month in severe, difficult-to-treat, chronic urticaria in a real-life setting. METHODS This prospective open-label study evaluated of 150 mg of omalizumab in severe urticaria defined by a 7-day urticaria activity score (UAS-7) higher than 30, a history of oral glucocorticoid use, and by suboptimal… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 14 times over the past 90 days. VIEW TWEETS
33 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…